Patents by Inventor Chun-Eung Park
Chun-Eung Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
Publication number: 20210300933Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.Type: ApplicationFiled: June 1, 2021Publication date: September 30, 2021Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG -
Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
Patent number: 11046702Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.Type: GrantFiled: April 17, 2020Date of Patent: June 29, 2021Assignee: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng -
IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
Publication number: 20200277298Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.Type: ApplicationFiled: April 17, 2020Publication date: September 3, 2020Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG -
IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
Publication number: 20190031669Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.Type: ApplicationFiled: September 28, 2018Publication date: January 31, 2019Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG -
Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
Patent number: 10100057Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.Type: GrantFiled: July 31, 2017Date of Patent: October 16, 2018Assignee: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng -
IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
Publication number: 20170349597Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.Type: ApplicationFiled: July 31, 2017Publication date: December 7, 2017Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG -
Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
Patent number: 9745310Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.Type: GrantFiled: February 25, 2016Date of Patent: August 29, 2017Assignee: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng -
IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
Publication number: 20160251361Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.Type: ApplicationFiled: February 25, 2016Publication date: September 1, 2016Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG -
Patent number: 8546576Abstract: There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder.Type: GrantFiled: June 3, 2009Date of Patent: October 1, 2013Assignee: SK Biopharmaceuticals Co., Ltd.Inventors: Ki-Ho Lee, Chun-Eung Park, Kyung-Hyun Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu
-
Patent number: 8513285Abstract: There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder.Type: GrantFiled: January 19, 2012Date of Patent: August 20, 2013Assignee: SK Biopharmaceuticals Co., Ltd.Inventors: Ki-Ho Lee, Chun-Eung Park, Kyung-Hyan Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu
-
Patent number: 8404730Abstract: Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.Type: GrantFiled: October 19, 2011Date of Patent: March 26, 2013Assignee: SK Biopharmaceuticals Co., Ltd.Inventors: Chun-Eung Park, Kyung-Hyun Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu, Coo-Min Chung, Hui-Ho Kim
-
Publication number: 20120122927Abstract: There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds.Type: ApplicationFiled: January 19, 2012Publication date: May 17, 2012Inventors: Ki-Ho Lee, Chun-Eung Park, Kyung-Hyan Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu
-
Publication number: 20120046312Abstract: Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.Type: ApplicationFiled: October 19, 2011Publication date: February 23, 2012Inventors: Chun-Eung Park, Kyung-Hyun Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu, Coo-Min Chung, Hui-Ho Kim
-
Patent number: 8101642Abstract: Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.Type: GrantFiled: June 3, 2009Date of Patent: January 24, 2012Assignee: SK Biopharmaceuticals Co., Ltd.Inventors: Chun-Eung Park, Kyung-Hyun Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu, Coo-Min Chung, Hui-Ho Kim
-
Publication number: 20100311789Abstract: Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.Type: ApplicationFiled: June 3, 2009Publication date: December 9, 2010Inventors: Chun-Eung Park, Kyung-Hyun Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu, Coo-Min Chung, Hui-Ho Kim
-
Publication number: 20090306140Abstract: There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I) or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds.Type: ApplicationFiled: June 3, 2009Publication date: December 10, 2009Inventors: Ki-Ho Lee, Chun-Eung Park, Kyung-Hyun Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu
-
Patent number: 7078537Abstract: The present invention relates to novel 1,2- or 1,3-diamine and amide compounds and pharmaceutically useful salts thereof and methods for treating central nervous system diseases. The present 1,2- or 1,3-diamine and amide compounds have high binding affinity to the sigma receptor.Type: GrantFiled: June 12, 2002Date of Patent: July 18, 2006Assignee: SK CorporationInventors: Yong-Moon Choi, Yong-Kil Kim, Chun-Eung Park, Eun-Ho Lee
-
Patent number: 6770659Abstract: Provided herein are racemic or enantiomerically enriched benzoyl piperidine compounds and pharmaceutically useful salts thereof, pharmaceutical compositions comprising an effective amount of racemic or enantiomerically enriched benzoyl piperidine compounds to treat central nervous system diseases and methods of treating central nervous system diseases in a mammal, in particular psychoses and cognition disorders.Type: GrantFiled: August 26, 2002Date of Patent: August 3, 2004Assignee: SK CorporationInventors: Yong-Moon Choi, Yong-Kil Kim, Jin-Uk Yoo, Eun-Ah Paek, Chun-Eung Park, Sung-Yong Seo, Coo-Min Chung, Joon Heo
-
Publication number: 20040044033Abstract: Provided herein are racemic or enantiomerically enriched benzoyl piperidine compounds and pharmaceutically useful salts thereof, pharmaceutical compositions comprising an effective amount of racemic or enantiomerically enriched benzoyl piperidine compounds to treat central nervous system diseases and methods of treating central nervous system diseases in a mammal, in particular psychoses and cognition disorders.Type: ApplicationFiled: August 26, 2002Publication date: March 4, 2004Inventors: Yong-Moon Choi, Yong-Kil Kim, Jin-Uk Yoo, Eun-Ah Paek, Chun-Eung Park, Sung-Yong Seo, Coo-Min Chung, Joon Heo
-
Publication number: 20030105079Abstract: The present invention relates to novel 1,2- or 1,3-diamine and amide compounds and pharmaceutically useful salts thereof and methods for treating central nervous system diseases. The present 1,2- or 1,3-diamine and amide compounds have high binding affinity to the sigma receptor.Type: ApplicationFiled: June 12, 2002Publication date: June 5, 2003Inventors: Yong-Moon Choi, Yong-Kil Kim, Chun-Eung Park, Eun-Ho Lee